{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-257910","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2021-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.055474+00:00","generated_at":"2026-06-29T07:16:44.671580+00:00","sec_items":["1.01","2.01","3.02","3.03","5.01","5.02","5.03","5.05","7.01","9.01","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Aerpio completes reverse merger with Aadi, changes name to Aadi Bioscience, raises $155M PIPE","bullets":["Former Aadi stockholders received ~0.3172 shares per Aadi share; post-merger ownership: Aadi 29.2%, former Aerpio 15.2%, PIPE 55.6%.","PIPE financing of $155M from 11.85M shares at ~$13.08/sh; Avoro Capital (affiliated with new director) invested $25M for ~1.91M shares.","New board of 7 directors: Caley Castelein (Chair), Neil Desai, Anupam Dalal, Karin Hehenberger, Behzad Aghazadeh, Richard Maroun; one vacancy.","Reverse stock split 15:1, name change to Aadi Bioscience, ticker symbol changes to AADI on Nasdaq effective Aug 27, 2021.","Contingent value rights (CVRs) issued to former Aerpio stockholders; each CVR entitles holder to 90% of net proceeds from certain milestone payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-257910","json":"https://secwatch.observer/filing/0001193125-21-257910.json","markdown":"https://secwatch.observer/filing/0001193125-21-257910.md","text":"https://secwatch.observer/filing/0001193125-21-257910.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/d119681d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T07:16:44.671580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20ed3fe090","claim":"Steven Prelack resigned as Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"23ad670cfe","claim":"Joseph Gardner resigned as Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"28111e76dc","claim":"Neil Desai was appointed as President, Chief Executive Officer and Secretary at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Board appointed Neil Desai, Ph.D., as the Company’s President, Chief Executive Officer and Secretary","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Chief Executive Officer and Secretary"}],"fact_type":"executive_change"},{"claim_id":"564069f472","claim":"Pravin Dugel resigned as Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a0ae058788","claim":"Regina Marek was terminated as Vice President, Principal Financial and Accounting Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Vice President, Principal Financial and Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"b776499fd8","claim":"Cheryl Cohen resigned as Director at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cfa3e29685","claim":"Lance Thibault was appointed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"Lance Thibault as the Company’s interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d0fef3884a","claim":"Joseph Gardner was terminated as Principal Executive Officer at Whitehawk Therapeutics, Inc..","evidence_excerpt":"the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312521257910/0001193125-21-257910-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Principal Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}